Hugging Face's logo

Datasets:
yicozy
/
dataset_pfs_hr_by_subgroup

Tags:
Dataset card Viewer Files Community
Dataset Viewer
Auto-converted to Parquet
Viewer
instruction
stringlengths
99
248
response
stringlengths
178
304
text
stringlengths
310
585
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is I or II patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is I or II patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with I or II ISS Disease Stage
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with I or II ISS Disease Stage ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for I or II ISS Disease Stage patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for I or II ISS Disease Stage patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at I or II ISS Disease Stage?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at I or II ISS Disease Stage? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for I or II ISS Disease Stage patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the I or II ISS Disease Stage group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the I or II ISS Disease Stage group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the I or II ISS Disease Stage group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the I or II ISS Disease Stage group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
What is the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
### Instruction: What is the PFS hazard ratio and 95% CI for I or II ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is I or II was 0.60 with a 95% confidence interval (CI) of (0.44, 0.81)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is III patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for ISS Disease Stage is III patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with III ISS Disease Stage
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with III ISS Disease Stage ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for III ISS Disease Stage patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for III ISS Disease Stage patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at III ISS Disease Stage?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at III ISS Disease Stage? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for III ISS Disease Stage patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the III ISS Disease Stage group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the III ISS Disease Stage group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the III ISS Disease Stage group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the III ISS Disease Stage group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
What is the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
### Instruction: What is the PFS hazard ratio and 95% CI for III ISS Disease Stage patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with ISS Disease Stage is III was 0.57 with a 95% confidence interval (CI) of (0.32, 1.03)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is <= 65 patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is <= 65 patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with <= 65 Age
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with <= 65 Age ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for <= 65 Age patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for <= 65 Age patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at <= 65 Age?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at <= 65 Age? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for <= 65 Age patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the <= 65 Age group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the <= 65 Age group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the <= 65 Age group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the <= 65 Age group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
What is the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
### Instruction: What is the PFS hazard ratio and 95% CI for <= 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is <= 65 was 0.51 with a 95% confidence interval (CI) of (0.35, 0.73)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is > 65 patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Age is > 65 patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with > 65 Age
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with > 65 Age ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for > 65 Age patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for > 65 Age patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at > 65 Age?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at > 65 Age? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for > 65 Age patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the > 65 Age group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the > 65 Age group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the > 65 Age group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the > 65 Age group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
What is the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
### Instruction: What is the PFS hazard ratio and 95% CI for > 65 Age patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Age is > 65 was 0.73 with a 95% confidence interval (CI) of (0.48, 1.12)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is North America patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is North America patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with North America Region
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with North America Region ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for North America Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for North America Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at North America Region?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at North America Region? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for North America Region patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the North America Region group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the North America Region group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the North America Region group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the North America Region group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
What is the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
### Instruction: What is the PFS hazard ratio and 95% CI for North America Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is North America was 0.19 with a 95% confidence interval (CI) of (0.05, 0.65)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Europe patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Europe patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Europe Region
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Europe Region ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Europe Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Europe Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Europe Region?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Europe Region? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Europe Region patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Europe Region group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Europe Region group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Europe Region group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Europe Region group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
What is the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
### Instruction: What is the PFS hazard ratio and 95% CI for Europe Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Europe was 0.72 with a 95% confidence interval (CI) of (0.52, 1.00)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Asia - Pacific patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Region is Asia - Pacific patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Asia - Pacific Region
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with Asia - Pacific Region ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Asia - Pacific Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for Asia - Pacific Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Asia - Pacific Region?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at Asia - Pacific Region? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Asia - Pacific Region patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Asia - Pacific Region group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the Asia - Pacific Region group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Asia - Pacific Region group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the Asia - Pacific Region group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
What is the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
### Instruction: What is the PFS hazard ratio and 95% CI for Asia - Pacific Region patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Region is Asia - Pacific was 0.45 with a 95% confidence interval (CI) of (0.24, 0.82)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 0-1 patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 0-1 patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 0-1 Baseline ECOG Score
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 0-1 Baseline ECOG Score ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 0-1 Baseline ECOG Score patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 0-1 Baseline ECOG Score patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 0-1 Baseline ECOG Score?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 0-1 Baseline ECOG Score? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 0-1 Baseline ECOG Score patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 0-1 Baseline ECOG Score group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 0-1 Baseline ECOG Score group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 0-1 Baseline ECOG Score group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 0-1 Baseline ECOG Score group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
What is the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
### Instruction: What is the PFS hazard ratio and 95% CI for 0-1 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 0-1 was 0.61 with a 95% confidence interval (CI) of (0.46, 0.81)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 2 patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline ECOG Score is 2 patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 2 Baseline ECOG Score
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients with 2 Baseline ECOG Score ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 2 Baseline ECOG Score patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: In the CANDOR study, what is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for 2 Baseline ECOG Score patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: Can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 2 Baseline ECOG Score?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: What’s the PFS hazard ratio and 95% CI for Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study for patients at 2 Baseline ECOG Score? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: In the CANDOR study, what’s the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd)? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: Could you provide the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients. Can you help?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: I’m looking for the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for 2 Baseline ECOG Score patients. Can you help? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 2 Baseline ECOG Score group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: What are the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for patients in the 2 Baseline ECOG Score group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 2 Baseline ECOG Score group?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: In the CANDOR study, can you tell me the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) for patients in the 2 Baseline ECOG Score group? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
What is the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study?
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
### Instruction: What is the PFS hazard ratio and 95% CI for 2 Baseline ECOG Score patients treated with Daratumumab+Carfilzomib+Dexamethasone (DKd) in the CANDOR study? ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline ECOG Score is 2 was 0.29 with a 95% confidence interval (CI) of (0.06, 1.34)
What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 patients
In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 was 0.41 with a 95% confidence interval (CI) of (0.19, 0.90)
### Instruction: What is the PFS hazard ratio and 95% CI of Daratumumab+Carfilzomib+Dexamethasone (DKd) in CANDOR study for Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 patients ### Response: In the CANDOR study, the progression-free survival (PFS) hazard ratio for Daratumumab+Carfilzomib+Dexamethasone (DKd) in patients with Baseline Creatinine Clearance (ML / Min) is >=15 To < 50 was 0.41 with a 95% confidence interval (CI) of (0.19, 0.90)
End of preview. Expand in Dataset Viewer.

Dataset Card for "dataset_pfs_hr_by_subgroup"

More Information needed

Downloads last month
0
Edit dataset card
Size of downloaded dataset files:
562 kB
Size of the auto-converted Parquet files:
562 kB
Number of rows:
8,668